Evidence map›Paper›PMID 38260261›Full record

ArticlebioRxiv : the preprint server for biology2024

Dihydrothiazolo ring-fused 2-pyridone antimicrobial compounds treat

Zongsen Zou, Chloe L P Obernuefemann, Pardeep Singh, Jerome S Pinkner, Wei Xu, Taylor M Nye, Karen W Dodson, Fredrik Almqvist, Scott J Hultgren, Michael G Caparon

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Zongsen ZouDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Chloe L P ObernuefemannDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Pardeep SinghDepartment of Chemistry, Umeå University, SE-90187 Umeå, Sweden.
Jerome S PinknerDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Wei XuDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Taylor M NyeDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Karen W DodsonDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Fredrik AlmqvistDepartment of Chemistry, Umeå University, SE-90187 Umeå, Sweden.
Scott J HultgrenDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Michael G CaparonDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
Institute for Women's Policy Research · USUmeå University · SE

Funding

Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTIU19AI157797 · NIAID · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J. · 2021 to 2025
$11.4M
MOLECULAR BASIS OF E. COLI ADHESINS IN BLADDER DISORDERSR01DK051406 · NIDDK · WASHINGTON UNIVERSITY · PI SCOTT J. HULTGREN · 1997 to 2026
$8.8M
Chemical disarming of drug resistance in Mycobacterium tuberculosisR01AI134847 · NIAID · WASHINGTON UNIVERSITY · PI ALMQVIST, FREDRIK, STALLINGS, CHRISTINA LEIGH · 2018 to 2021
$2.7M
Novel Therapeutic Approach to Invasive Group A Streptococcal DiseaseR21AI163825 · NIAID · WASHINGTON UNIVERSITY · PI CAPARON, MICHAEL G. · 2022 to 2023
$432k
NIAID NIH HHS R01 AI134847NIAID NIH HHS R21 AI163825NIAID NIH HHS U19 AI157797NIDDK NIH HHS R01 DK051406
6 · The paper itself

Abstract

We have developed GmPcides from a peptidomimetic dihydrothiazolo ring-fused 2-pyridone scaffold that have antimicrobial activities against a broad-spectrum of Gram-positive pathogens. Here we examine the treatment efficacy of GmPcides using skin and soft tissue infection (SSTI) and biofilm formation models by

Identifiers

PMID38260261
PMCPMC10802287
OpenAlexW4390656899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.